Navigation Links
Sinovac to Participate in Two Upcoming Investor Conferences
Date:10/29/2008

BEIJING, Oct. 29 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that it is scheduled to present at two upcoming investor conferences, including the Oppenheimer 19th Annual Healthcare Conference in New York City and the Credit Suisse Asian Healthcare Conference in Beijing, China.

Ms. Vanessa Wu, Senior Financial Manager, is scheduled to present on Tuesday, November 4, 2008 at 3:20 pm at Oppenheimer 19th Annual Healthcare Conference, at the Waldorf-Astoria Hotel in New York, NY.

Dr. Weidong Yin, Chairman, President and CEO, is scheduled to attend the Credit Suisse Asian Healthcare Conference on November 5 and 6, at The Westin Beijing Hotel at Financial Street in Beijing, China.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington

The Ruth Group

Tel: +1-646-536-7017

Email: scarrington@theruthgroup.com

Janine McCargo

The Ruth Group

Tel: +1-646-536-7033

Email: jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
2. Sinovac Biotech Holds 2007 Annual General Meeting
3. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
4. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
5. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
6. Sinovac Adjourns Annual General Meeting
7. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
8. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... DIEGO , Feb. 3, 2016   ... company with the first pluripotent stem cell-derived islet ... diabetes in clinical-stage development, today announced that ViaCyte ... Pharmaceutical Companies of Johnson & Johnson, have agreed ... group into ViaCyte.  The agreement provides ViaCyte with ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma ... company that applies its innovative TransCon technology to address ... at an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare ... Date:  , Wednesday, February 10, 2016 Time:  , ... www.ascendispharma.com . --> An audio webcast of ...
(Date:2/3/2016)... Colorado (PRWEB) , ... February 03, 2016 , ... ... hospitals, has established a new office dedicated to the North American healthcare market. ... turnkey solutions to healthcare facilities. The company will provide new pneumatic tube ...
(Date:2/3/2016)... ... February 03, 2016 , ... Resilinc ... summarizes and analyzes nearly 750 unique supply chain notifications and alerts generated by ... , Supply chain risk management practitioners subscribe to the EventWatch service to receive ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):